Biotech Values

[dav1234]

Halozyme's Hylenex meet's main goal of study
Halozyme Therapeutics' (HALO) Hylenex treatment met the main goal of a trial in which a recombinant and a new formulation of the therapy were assessed.
The study compared the use of Hylenex as a pretreatment for Type I diabetes patients receiving insulin injections compared with subjects who didn't receive pre-treatment.
Hylenex achieved non-inferiority of hemoglobin A1C levels at six months, the primary endpoint. A1C indicates how much sugar is in the blood.
Hylenex also reduced rates of hypoglycemia (low blood sugar), which the lead investigator of the study says is a key unmet need.
Shares are +9%
http://seekingalpha.com/pr/9413123-halozyme-announces-that-consistent-1-trial-of-hylenex-recombinant-met-primary-endpoint